You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFenoldopam
Accession NumberDB00800  (APRD00969)
TypeSmall Molecule
GroupsApproved
DescriptionA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. [PubChem]
Structure
Thumb
Synonyms
Fenoldopam
Fénoldopam
Fenoldopam
Fenoldopamum
External Identifiers
  • SKF 82526
  • SKF 82526-J
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CorlopamInjection, solution10 mg/mLIntravenousHospira, Inc.1997-09-23Not applicableUs
CorlopamInjection, solution10 mg/mLIntravenousHospira, Inc.1997-09-23Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fenoldopam mesylate
67227-57-0
Thumb
  • InChI Key: CVKUMNRCIJMVAR-UHFFFAOYSA-N
  • Monoisotopic Mass: 401.0699862
  • Average Mass: 401.86
DBSALT000945
Categories
UNIIINU8H2KAWG
CAS number67227-56-9
WeightAverage: 305.756
Monoisotopic: 305.08187109
Chemical FormulaC16H16ClNO3
InChI KeyTVURRHSHRRELCG-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
IUPAC Name
6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
SMILES
OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
Pharmacology
IndicationFor the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.
Structured Indications
PharmacodynamicsFenoldopam is an agonist at D1-like dopamine receptors, binds to α2-adrenoceptors, increasing renal blood flow.
Mechanism of actionFenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β-adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D2-like dopamine receptors, or α or β -adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(1B) dopamine receptorProteinyes
agonist
HumanP21918 details
D(1A) dopamine receptorProteinyes
agonist
HumanP21728 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinunknown
antagonist
HumanP18825 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-1B adrenergic receptorProteinunknownNot AvailableHumanP35368 details
Alpha-1D adrenergic receptorProteinunknownNot AvailableHumanP25100 details
Alpha-1A adrenergic receptorProteinunknownNot AvailableHumanP35348 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Methylation, glucuronidation, and sulfation are the main routes of conjugation.

Route of eliminationRadiolabeled studies show that about 90% of infused fenoldopam is eliminated in urine, 10% in feces. Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Only 4% of the administered dose is excreted unchanged.
Half lifeThe elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.
ClearanceNot Available
ToxicityThe most likely reaction of overdose would be excessive hypotension which should be treated with drug discontinuation and appropriate supportive measures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Fenoldopam.Experimental
AcebutololFenoldopam may increase the hypotensive activities of Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fenoldopam.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Fenoldopam.Approved, Investigational
AliskirenFenoldopam may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololFenoldopam may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanFenoldopam may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineFenoldopam may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Fenoldopam.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fenoldopam.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Fenoldopam.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Fenoldopam.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fenoldopam.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Fenoldopam.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Fenoldopam.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Fenoldopam.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Fenoldopam.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fenoldopam.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fenoldopam.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Fenoldopam.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenoldopam.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Fenoldopam.Experimental
BarbitalBarbital may increase the hypotensive activities of Fenoldopam.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Fenoldopam.Approved
BenazeprilBenazepril may increase the hypotensive activities of Fenoldopam.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Fenoldopam.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Fenoldopam.Withdrawn
BepridilFenoldopam may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Fenoldopam.Approved
BethanidineBethanidine may increase the hypotensive activities of Fenoldopam.Approved
BimatoprostFenoldopam may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Fenoldopam.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fenoldopam.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Fenoldopam.Approved, Investigational
BretyliumFenoldopam may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Fenoldopam.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Fenoldopam.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fenoldopam.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Fenoldopam.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fenoldopam.Approved, Investigational
BupranololFenoldopam may increase the hypotensive activities of Bupranolol.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Fenoldopam.Approved
CandesartanCandesartan may increase the hypotensive activities of Fenoldopam.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Fenoldopam.Experimental
CaptoprilFenoldopam may increase the hypotensive activities of Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fenoldopam.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Fenoldopam.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Fenoldopam.Approved
CarvedilolFenoldopam may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololFenoldopam may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideFenoldopam may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenoldopam.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Fenoldopam.Approved
CilazaprilFenoldopam may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fenoldopam.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Fenoldopam.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Fenoldopam.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenoldopam.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Fenoldopam.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fenoldopam.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fenoldopam.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Fenoldopam.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Fenoldopam.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Fenoldopam.Approved
DebrisoquinFenoldopam may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineFenoldopam may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fenoldopam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fenoldopam.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Fenoldopam.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Fenoldopam.Approved
DihydralazineFenoldopam may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Fenoldopam.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Fenoldopam.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Fenoldopam.Approved
DorzolamideFenoldopam may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Fenoldopam.Approved
DuloxetineFenoldopam may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineFenoldopam may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Fenoldopam.Approved
EnalaprilEnalapril may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
EnalaprilatFenoldopam may increase the hypotensive activities of Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Fenoldopam.Approved
EpoprostenolFenoldopam may increase the hypotensive activities of Epoprostenol.Approved
EprosartanFenoldopam may increase the hypotensive activities of Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Fenoldopam.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Fenoldopam.Approved
FelodipineFenoldopam may increase the hypotensive activities of Felodipine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Fimasartan.Approved
FosinoprilFosinopril may increase the hypotensive activities of Fenoldopam.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Fenoldopam.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Fenoldopam.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Fenoldopam.Approved
GuanethidineFenoldopam may increase the hypotensive activities of Guanethidine.Approved
GuanfacineFenoldopam may increase the hypotensive activities of Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Halothane.Approved, Vet Approved
HexamethoniumFenoldopam may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Fenoldopam.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Fenoldopam.Approved
HydralazineFenoldopam may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideFenoldopam may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Fenoldopam.Approved
IloprostIloprost may increase the hypotensive activities of Fenoldopam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imipramine.Approved
IndapamideFenoldopam may increase the hypotensive activities of Indapamide.Approved
IndenololFenoldopam may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminFenoldopam may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Fenoldopam.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Fenoldopam.Withdrawn
IrbesartanFenoldopam may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Fenoldopam.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Fenoldopam.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Fenoldopam.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Fenoldopam.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Fenoldopam.Approved
KetanserinFenoldopam may increase the hypotensive activities of Ketanserin.Investigational
LabetalolLabetalol may increase the hypotensive activities of Fenoldopam.Approved
LacidipineFenoldopam may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Fenoldopam.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Fenoldopam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Fenoldopam.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Levobupivacaine.Approved
LevodopaFenoldopam may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Levosimendan.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Fenoldopam.Approved, Investigational
LofexidineFenoldopam may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Fenoldopam.Approved
MacitentanFenoldopam may increase the hypotensive activities of Macitentan.Approved
ManidipineFenoldopam may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Fenoldopam.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Fenoldopam.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Fenoldopam.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Fenoldopam.Approved
MethohexitalMethohexital may increase the hypotensive activities of Fenoldopam.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Fenoldopam.Approved
MethyldopaFenoldopam may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Fenoldopam.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fenoldopam.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Fenoldopam.Approved
MetipranololFenoldopam may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Fenoldopam.Approved
MetoprololMetoprolol may increase the hypotensive activities of Fenoldopam.Approved, Investigational
MetyrosineFenoldopam may increase the hypotensive activities of Metyrosine.Approved
MibefradilFenoldopam may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Fenoldopam.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Fenoldopam.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Fenoldopam.Approved
MoexiprilMoexipril may increase the hypotensive activities of Fenoldopam.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Fenoldopam.Approved
MorphineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Morphine.Approved, Investigational
MoxonidineFenoldopam may increase the hypotensive activities of Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nabilone.Approved, Investigational
NadololFenoldopam may increase the hypotensive activities of Nadolol.Approved
NaftopidilFenoldopam may increase the hypotensive activities of Naftopidil.Investigational
NebivololFenoldopam may increase the hypotensive activities of Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Fenoldopam.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Fenoldopam.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Fenoldopam.Approved
NicorandilNicorandil may increase the hypotensive activities of Fenoldopam.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Fenoldopam.Approved
NiguldipineFenoldopam may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineFenoldopam may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Fenoldopam.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Fenoldopam.Approved
NitrendipineFenoldopam may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Fenoldopam.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Fenoldopam.Approved
ObinutuzumabFenoldopam may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Fenoldopam.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Fenoldopam.Approved, Investigational
OmapatrilatFenoldopam may increase the hypotensive activities of Omapatrilat.Investigational
OxprenololFenoldopam may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Fenoldopam.Approved
PargylinePargyline may increase the hypotensive activities of Fenoldopam.Approved
PenbutololFenoldopam may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
PentoliniumFenoldopam may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Fenoldopam.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Fenoldopam.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Fenoldopam.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Fenoldopam.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Fenoldopam.Approved
PhenoxybenzamineFenoldopam may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Fenoldopam.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Fenoldopam.Approved
PinacidilFenoldopam may increase the hypotensive activities of Pinacidil.Withdrawn
PindololFenoldopam may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Fenoldopam.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Fenoldopam.Withdrawn
PolythiazideFenoldopam may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the hypotensive activities of Fenoldopam.Approved
PrimidonePrimidone may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Fenoldopam.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fenoldopam.Approved
QuinaprilFenoldopam may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Fenoldopam.Approved
RamiprilRamipril may increase the hypotensive activities of Fenoldopam.Approved
RasagilineRasagiline may increase the hypotensive activities of Fenoldopam.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Fenoldopam.Approved
RescinnamineFenoldopam may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Fenoldopam.Approved
RilmenidineFenoldopam may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatFenoldopam may increase the hypotensive activities of Riociguat.Approved
RisperidoneFenoldopam may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabFenoldopam may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Fenoldopam.Withdrawn
SaprisartanFenoldopam may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Fenoldopam.Approved, Investigational, Vet Approved
SelexipagFenoldopam may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Fenoldopam.Approved, Investigational
SitaxentanFenoldopam may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Fenoldopam.Approved
SpiraprilFenoldopam may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Fenoldopam.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sufentanil.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Fenoldopam.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tamsulosin.Approved, Investigational
TelmisartanFenoldopam may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilFenoldopam may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Fenoldopam.Approved
TerlipressinFenoldopam may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Thioridazine.Approved
TiboloneFenoldopam may increase the hypotensive activities of Tibolone.Approved
TicrynafenFenoldopam may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Fenoldopam.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fenoldopam.Approved
TolazolineTolazoline may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypotensive activities of Fenoldopam.Approved
TorasemideTorasemide may increase the hypotensive activities of Fenoldopam.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Fenoldopam.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fenoldopam.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Fenoldopam.Approved
TravoprostTravoprost may increase the hypotensive activities of Fenoldopam.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Fenoldopam.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Fenoldopam.Approved
TrichlormethiazideFenoldopam may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinFenoldopam may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanFenoldopam may increase the hypotensive activities of Trimethaphan.Approved
UdenafilUdenafil may increase the antihypertensive activities of Fenoldopam.Approved, Investigational
UnoprostoneFenoldopam may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Fenoldopam.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Fenoldopam.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Fenoldopam.Approved
VinpocetineFenoldopam may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineFenoldopam may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Fenoldopam.Approved, Vet Approved
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US4197297
General ReferencesNot Available
External Links
ATC CodesC01CA19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (239 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.7784
Caco-2 permeable-0.5345
P-glycoprotein substrateSubstrate0.8329
P-glycoprotein inhibitor INon-inhibitor0.9142
P-glycoprotein inhibitor IINon-inhibitor0.8567
Renal organic cation transporterNon-inhibitor0.6062
CYP450 2C9 substrateNon-substrate0.8216
CYP450 2D6 substrateNon-substrate0.7124
CYP450 3A4 substrateNon-substrate0.5301
CYP450 1A2 substrateNon-inhibitor0.713
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8316
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7436
Ames testNon AMES toxic0.7166
CarcinogenicityNon-carcinogens0.9006
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.7788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6864
hERG inhibition (predictor II)Inhibitor0.8833
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Bedford laboratories
  • Pharmaforce inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous10 mg/mL
Prices
Unit descriptionCostUnit
Fenoldopam 10 mg/ml ampule213.75USD ml
Corlopam 10 mg/ml ampul81.9USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility4000 mg/LNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.272 mg/mLALOGPS
logP2.39ALOGPS
logP1.92ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)8.12ChemAxon
pKa (Strongest Basic)10.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.68 m3·mol-1ChemAxon
Polarizability30.71 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassNot Available
Direct ParentBenzazepines
Alternative Parents
Substituents
  • Benzazepine
  • Chlorocatechol
  • 3-chlorocatechol
  • 2-halophenol
  • 3-halophenol
  • 1,2-diphenol
  • Aralkylamine
  • Phenol
  • Azepine
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, He D, Huang L, Yang C, Wang X, Zhou L, Jose PA: D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009 May;27(5):1033-41. doi: 10.1097/HJH.0b013e3283293c7b. [PubMed:19293728 ]
  4. Dhasmana KM, Villalon CM, Zhu YN, Parmar SS: The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res. 1993 May-Jun;27(4):335-47. [PubMed:8103596 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, He D, Huang L, Yang C, Wang X, Zhou L, Jose PA: D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009 May;27(5):1033-41. doi: 10.1097/HJH.0b013e3283293c7b. [PubMed:19293728 ]
  3. Dhasmana KM, Villalon CM, Zhu YN, Parmar SS: The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res. 1993 May-Jun;27(4):335-47. [PubMed:8103596 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23